FOOD INNOVATION & SCIENCE

A fermentation-derived egg protein is finally landing in a product on U.S. shelves. Whether that becomes a pattern or a press release depends on what happens next.

Key Takeaways

• Onego Bio and Zen Waffles announced a commercial partnership September 9 to put precision-fermented Bioalbumen into high-protein waffles.
• Bioalbumen is fermentation-derived ovalbumin, the principal protein in egg white, produced using Trichoderma reesei.
• Because ovalbumin drives foaming, gelling and binding, this is a functionality story, not just another alt-protein launch.
• FDA issued a “no questions” GRAS response for Bioalbumen in September 2025, clearing the main U.S. regulatory hurdle.
• The Zen Waffles deal proves a customer will formulate with the ingredient. It does not prove volume or economics at scale.
• The real test ahead is repeat orders, not a second launch.

A Functional Ingredient, Not Just a Protein Source

Egg whites are hard to replace because ovalbumin does several jobs at once: aeration, structure, binding, gelling. Onego makes it by fermenting Trichoderma reesei, then separating, purifying and drying it into a powder it says performs across cakes, cookies, meringues, breads, pasta and batters.

Those are manufacturer claims. They still need validating inside each customer’s own formulation and processing line. That distinction is the whole commercial question: precision fermentation’s strongest case is not a sustainability story told to consumers, it is a formulation problem solved for a product developer.

Regulatory Clearance Is the Easy Part

FDA’s “no questions” GRAS response in September 2025 opened the door to bakery, beverage, confectionery, sauce and meat-alternative applications. That removed a barrier, not the barrier. Onego has also entered a collaboration with Sigma to evaluate Bioalbumen’s functionality, and says it has worked with more than 25 CPG companies. Zen Waffles is the visible endpoint of that pipeline: development, clearance, trials, now a named product.

Scale and Economics Are the Hard Part

Avian flu has made egg supply and pricing volatile enough that manufacturers may start valuing production stability as highly as sustainability. Fermentation sidesteps flock-level disease risk entirely. Onego says Bioalbumen can become cost-competitive with cage-free egg-white powder at scale, but that is a company claim, not an independently verified one.

The company has raised $40 million in Series A funding plus $10 million from Business Finland, and later added €14 million from the European Innovation Council Accelerator. It is currently running contract manufacturing while planning a dedicated Wisconsin facility. Producing kilograms for trials is one problem. Producing tonnes, consistently, at a price manufacturers will keep paying, is the actual industry-defining one.

That reframes how food companies should evaluate the ingredient: not price per kilogram alone, but functionality delivered per dollar in the finished product, weighed against shelf stability, consistency and insulation from supply shocks.

Practical Implications for Food Manufacturers

Bakery and prepared-food R&D teams now have another functional protein platform to evaluate where egg-white functionality is important.

Procurement teams should assess fermentation-derived proteins not only against spot egg prices but against longer-term supply volatility and specification consistency.

Regulatory and allergen teams must remain involved. Bioalbumen contains ovalbumin, meaning it remains an egg protein and should be treated as an egg allergen. Precision fermentation does not make the protein allergen-free.

Onego and Zen Waffles have shown that a fermentation-derived egg protein can reach a real product on a real shelf. What happens after that first order, whether Bioalbumen becomes an ordinary line item in a formulation or stays a one-off pilot, is the number worth tracking from here.

Related on GFI: Precision-Fermented Dairy Proteins Have Solved the Biology. The Race Now Is Cost and Precision Fermentation Is Entering a New Phase. The Biggest Challenge Is No Longer the Science. It Is Commercial Scale.

---

Sources

1. Onego Bio. Onego Bio and Zen Waffles Announce Commercial Partnership to Bring Bioalbumen to the High-Protein Breakfast Category. September 9, 2026.
2. Baking Business. Onego Bio enters Zen Waffles partnership. September 14, 2026.
3. Onego Bio. Onego Bio Receives FDA “No Questions” Letter on GRAS Status of Bioalbumen. September 22, 2025.
4. Onego Bio. Bioalbumen Customer Resource Hub and technical guidance.
5. Onego Bio. Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience. March 5, 2026.
6. Onego Bio. Series A and scale-up announcements. 2024.
7. Good Food Institute. 2026 State of the Industry: Fermentation for Meat, Seafood, Eggs, Dairy and Ingredients.